Australia's Clarity Pharmaceuticals surges on FDA fast track status for prostate cancer drug
24/01/2025 02:24
** Shares of Clarity Pharmaceuticals CU6.AX up ~2% at
A$4.135, set for a fourth consecutive session of gain
** Radiopharma co says the U.S. Food and Drug Administration
has granted Fast Track Designation for its prostate cancer drug,
64Cu-SAR-bisPSMA
** Says the drug has several advantages over currently
approved ones, including improved diagnostic performance and
flexible imaging schedule, among others
** Stock rises as much as 15.5% earlier in the day, marking
its biggest intraday pct gain since Dec. 18, 2024
** About 2 mln shares change hands, 1.1x the 30-avg
** Stock more than doubled in value last year
(Reporting by Kumar Tanishk in Bengaluru)
((Tanishk.Kumar@thomsonreuters.com;))
Recent news on Clarity Pharmaceuticals
See all newsBrief: Clarity Pharmaceuticals Signs Commercial Manufacturing Agreement
Brief: Clarity Signs A Large-Scale Manufacturing Supply Agreement For Copper-64 With Theragenics
Brief: Clarity Pharmaceuticals Signs A Large-Scale Manufacturing Supply Agreement
Australia's Clarity Pharmaceuticals rises on bagging cancer detection agent supply
Australia's Clarity Pharma surges as US FDA approves trial